Interview with James Lanthier, CEO of Mindset Pharma

HAVN VS. Mindmed – Whose Cluster Headache Treatment Is Better?

Havn Life Sciences, (CSE: HAVN / OTC: HAVLF / FRA: 5NP) has started to be mentioned more and more on this channel, particularly in our “This Week In Psychedelic Stocks” segment.
In light of HAVN’s recent news that it is entering the cluster headaches segment, we are having a discussion with the company CEO, Tim Moore.

HAVN is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing innovative mental health treatment to support brain health and enhance the capabilities of the mind.

Interestingly enough, HAVN Labs is of the first companies to receive permission from Health Canada to work with psilocybin in 2020.

The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024) and is expected to experience huge demand for Reishi and Cordyceps. This is why HAVN Life has decided to pursue formulations with these mushrooms.

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (HAVN) via digital communications. We have been paid ($1000) .

https://havnlife.com/
CSE: HAVN | OTC: HAVLF | FRA: 5NP

#HAVN #HAVNLifeSciences #Mindmed

In today’s episode, we will be discussing why Psychedelic Stocks, like MindMed (MMED / MMEDF) and Compass Pathways (CMPS) are not Cannabis 2.0, and why psychedelic stock prices will not follow the same path. For those who remember, Pot Stocks skyrocketed on the news of legalization, and then quickly tumbled back down to earth.

Some have dismissed companies like MindMed (MMED/MMEDF) and Compass Pathways (CMPS) as just the cannabis hype 2.0.
This, however, could not be further from the truth.
To be clear stocks like, MindMed Stock ( MMED : NEO market) and (MMEDF : OTC market), and Compass Pathways stock, ticker symbol CMPS are nothing like cannabis stocks.
To explain why, we are going to discuss an article entitled , “Why The Psychedelics Market is not Cannabis 2.0”, written by Jeff Siegel.

Psychedelic stocks are comparables to biotech companies these days. The prospect of promising research is pushing valuations upwards There are plenty of psychedelic stocks have experienced triple-digit returns in the last twelve months:

MindMed Stock MMED/MMEDF): 864%
Numinuss Wellness (NUMI): 555%
Revive Therapeutics (RVV): 166%
Compass Pathways (CMPS): 88%

The psychedelic industry is only just commencing. Other psychedelic stocks will soon penetrate the market and early investors can benefits from the shroom boom with 10X to 20X gains.

#psychedelicstocks #shroomstocks #mindmedstock

https://www.benzinga.com/markets/cannabis/21/01/19008810/why-the-psychedelics-market-is-not-cannabis-2-0

Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Buy tickets for Plant Medicine Week in Malta, April 5th-8th by using our promo link: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC

Get 50% off tickets via the link above or by inputting code PSYC at the checkout over at plantmedicineweek.com/tickets!

Do you both love learning about psychedelics, and need a vacation in beautiful Malta? Well you are in luck, because Microdose.buzz is hosting a one of a kind event next month.

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

At the event you will be able to learn about the medical benefits, research, and business of psychedelics, as well as marijuana. The all-star studded line-up includes representatives from companies such as atai Life Sciences (ATAI), Awakn Life Sciences (AWKN, AWKNF) and more.

From panels on psychedelics and sex, to how to make money investing in psychedelics, this event will have it all. Plus…AFTER PARTIES!

No matter if you want to learn about LSD, MDMA, psilocybin, ketamine or more, this event will have it all. We already know that psychedelics can help with mental health, now hear it first hand from the scientists themselves.

#Psychedelics #MentalHealth #Microdose